[{"id":"1d278134-0537-4b56-865d-be1ee7a40e61","acronym":"IREN","url":"https://clinicaltrials.gov/study/NCT07041606","created_at":"2025-06-28T13:39:22.517Z","updated_at":"2025-06-28T13:39:22.517Z","phase":"","brief_title":"An Observational Study of Molecular profIling of Advanced and aggRessive ENdometrial Cancer and 1-st Line Treatment Approaches in Russian Federation","source_id_and_acronym":"NCT07041606 - IREN","lead_sponsor":"AstraZeneca","biomarkers":" PD-L1","pipe":" | ","alterations":" MSI-H/dMMR","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 06/30/2025","start_date":" 06/30/2025","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-06-27"},{"id":"28c966c6-aa0a-48ec-89d0-5286ecccf723","acronym":"","url":"https://clinicaltrials.gov/study/NCT02912559","created_at":"2021-01-18T14:17:52.733Z","updated_at":"2025-02-25T12:26:32.593Z","phase":"Phase 3","brief_title":"Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair","source_id_and_acronym":"NCT02912559","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MLH1 • MSH6 • MSH2 • CD4","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MLH1 • MSH6 • MSH2 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • 5-fluorouracil • Cotellic (cobimetinib) • oxaliplatin • leucovorin calcium • fluorouracil topical"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 700","initiation":"Initiation: 10/16/2017","start_date":" 10/16/2017","primary_txt":" Primary completion: 04/02/2025","primary_completion_date":" 04/02/2025","study_txt":" Completion: 04/02/2025","study_completion_date":" 04/02/2025","last_update_posted":"2025-02-24"},{"id":"c79faf97-f729-4398-957b-5d83e409d779","acronym":"COMMIT","url":"https://clinicaltrials.gov/study/NCT02997228","created_at":"2021-01-18T14:45:08.921Z","updated_at":"2025-02-25T12:26:35.429Z","phase":"Phase 3","brief_title":"Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study","source_id_and_acronym":"NCT02997228 - COMMIT","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • MSI • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" PD-L1 expression • BRAF V600E • MSI-H/dMMR","tags":["PD-L1 • MSI • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF V600E • MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • 5-fluorouracil • oxaliplatin • Aybintio (bevacizumab biosimilar) • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Jobevne (bevacizumab-nwgd) • fluorouracil topical • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 01/19/2018","start_date":" 01/19/2018","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-02-24"},{"id":"34e7c443-a4b5-4fa2-810c-e931f9bf2ab9","acronym":"SGNEGFRd2-001","url":"https://clinicaltrials.gov/study/NCT05983133","created_at":"2023-08-09T14:09:24.911Z","updated_at":"2025-02-25T13:55:26.636Z","phase":"Phase 1","brief_title":"A Study of SGN-EGFRd2 in Advanced Solid Tumors","source_id_and_acronym":"NCT05983133 - SGNEGFRd2-001","lead_sponsor":"Seagen Inc.","biomarkers":" EGFR • ALK • MSI","pipe":" | ","alterations":" EGFR mutation • MSI-H/dMMR • ALK rearrangement","tags":["EGFR • ALK • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • MSI-H/dMMR • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PF-08046052"],"overall_status":"Recruiting","enrollment":" Enrollment 275","initiation":"Initiation: 11/14/2023","start_date":" 11/14/2023","primary_txt":" Primary completion: 07/31/2027","primary_completion_date":" 07/31/2027","study_txt":" Completion: 09/30/2028","study_completion_date":" 09/30/2028","last_update_posted":"2025-02-20"},{"id":"5b604fcd-b187-4ac2-8cb5-8e6c3fc1616c","acronym":"CheckMate 8KX","url":"https://clinicaltrials.gov/study/NCT03656718","created_at":"2021-01-18T17:56:53.970Z","updated_at":"2025-02-25T13:52:39.029Z","phase":"Phase 1/2","brief_title":"A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)","source_id_and_acronym":"NCT03656718 - CheckMate 8KX","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Opdivo Qvantig (nivolumab and hyaluronidase-nvhy)"],"overall_status":"Completed","enrollment":" Enrollment 139","initiation":"Initiation: 10/29/2018","start_date":" 10/29/2018","primary_txt":" Primary completion: 09/07/2022","primary_completion_date":" 09/07/2022","study_txt":" Completion: 09/12/2024","study_completion_date":" 09/12/2024","last_update_posted":"2025-02-20"},{"id":"53c57014-eed8-45c6-afa4-43da3ec376e4","acronym":"BGB-A317-214","url":"https://clinicaltrials.gov/study/NCT05116085","created_at":"2021-11-10T14:13:08.209Z","updated_at":"2025-02-25T14:08:28.217Z","phase":"Phase 2","brief_title":"Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Patients With Colorectal Cancer","source_id_and_acronym":"NCT05116085 - BGB-A317-214","lead_sponsor":"BeiGene","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 01/26/2022","start_date":" 01/26/2022","primary_txt":" Primary completion: 09/26/2023","primary_completion_date":" 09/26/2023","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2025-02-18"},{"id":"ed7e0a8d-7121-41ed-982b-5af9f5bc5b3a","acronym":"NRG-GY025","url":"https://clinicaltrials.gov/study/NCT05112601","created_at":"2021-11-09T20:21:18.547Z","updated_at":"2025-02-25T14:16:28.432Z","phase":"Phase 2","brief_title":"Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma","source_id_and_acronym":"NCT05112601 - NRG-GY025","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 06/02/2022","start_date":" 06/02/2022","primary_txt":" Primary completion: 04/30/2026","primary_completion_date":" 04/30/2026","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2025-02-18"},{"id":"03ad2ae1-62eb-4ee9-9973-fa23d5f2634d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05904496","created_at":"2023-06-15T17:08:23.801Z","updated_at":"2025-02-25T14:18:02.487Z","phase":"Phase 1","brief_title":"A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05904496","lead_sponsor":"BeiGene","biomarkers":" TMB • MSI","pipe":" | ","alterations":" TMB-H • MSI-H/dMMR","tags":["TMB • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H • MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • BGB-30813"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 07/19/2023","start_date":" 07/19/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-17"},{"id":"2c844ff3-38e3-4e1a-ab45-51650b975490","acronym":"ST316-101","url":"https://clinicaltrials.gov/study/NCT05848739","created_at":"2023-05-08T15:04:02.971Z","updated_at":"2025-02-25T14:17:54.068Z","phase":"Phase 1","brief_title":"A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors","source_id_and_acronym":"NCT05848739 - ST316-101","lead_sponsor":"Sapience Therapeutics","biomarkers":" PD-L1 • MSI • BRCA","pipe":" | ","alterations":" PD-L1 expression • MSI-H/dMMR • BRCA mutation","tags":["PD-L1 • MSI • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MSI-H/dMMR • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • irinotecan • Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil) • leucovorin calcium • ST316"],"overall_status":"Recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 06/05/2023","start_date":" 06/05/2023","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 05/31/2027","study_completion_date":" 05/31/2027","last_update_posted":"2025-02-17"},{"id":"59d4a003-e862-4682-ad7b-ffa3cb7e3e25","acronym":"","url":"https://clinicaltrials.gov/study/NCT03190174","created_at":"2021-01-18T15:43:45.733Z","updated_at":"2025-02-25T14:15:01.560Z","phase":"Phase 1/2","brief_title":"Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers","source_id_and_acronym":"NCT03190174","lead_sponsor":"Sarcoma Oncology Research Center, LLC","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • sirolimus • Fyarro (nanoparticle albumin-bound rapamycin)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 08/24/2017","start_date":" 08/24/2017","primary_txt":" Primary completion: 12/01/2021","primary_completion_date":" 12/01/2021","study_txt":" Completion: 12/02/2021","study_completion_date":" 12/02/2021","last_update_posted":"2025-02-17"},{"id":"6553092f-70e4-434d-af85-c9de431dfb02","acronym":"","url":"https://clinicaltrials.gov/study/NCT03290937","created_at":"2021-01-18T16:15:28.855Z","updated_at":"2025-02-25T14:07:03.272Z","phase":"Phase 1","brief_title":"Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer","source_id_and_acronym":"NCT03290937","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR • RAS mutation","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • irinotecan • utomilumab (PF-05082566) • Datalai (cetuximab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 12/27/2017","start_date":" 12/27/2017","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-17"},{"id":"742fd153-ce97-4ee4-b30a-065c666ab97f","acronym":"UNICORN","url":"https://clinicaltrials.gov/study/NCT05845450","created_at":"2023-05-06T15:04:38.828Z","updated_at":"2025-02-25T14:09:41.563Z","phase":"Phase 2","brief_title":"Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)","source_id_and_acronym":"NCT05845450 - UNICORN","lead_sponsor":"Gruppo Oncologico del Nord-Ovest","biomarkers":" HER-2 • KRAS • BRAF • TMB • MSI • POLE • POLD1","pipe":" | ","alterations":" HER-2 positive • MSI-H/dMMR • KRAS G12C • HER-2 amplification • HER-2 mutation • POLE mutation • KRAS wild-type • RAS wild-type • KRAS G12 • POLD1 mutation • HER-2 positive + HER-2 overexpression • HER-2 positive + RAS wild-type","tags":["HER-2 • KRAS • BRAF • TMB • MSI • POLE • POLD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • MSI-H/dMMR • KRAS G12C • HER-2 amplification • HER-2 mutation • POLE mutation • KRAS wild-type • RAS wild-type • KRAS G12 • POLD1 mutation • HER-2 positive + HER-2 overexpression • HER-2 positive + RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Vectibix (panitumumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Lumakras (sotorasib) • balstilimab (AGEN2034) • botensilimab (AGEN1181)"],"overall_status":"Recruiting","enrollment":" Enrollment 112","initiation":"Initiation: 05/11/2023","start_date":" 05/11/2023","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2025-02-17"},{"id":"4ef750b4-3fb6-4689-b95f-2c678d9c99e2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04777994","created_at":"2021-03-02T12:52:26.138Z","updated_at":"2025-02-25T14:40:45.849Z","phase":"Phase 1","brief_title":"Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors","source_id_and_acronym":"NCT04777994","lead_sponsor":"AbbVie","biomarkers":" PD-L1 • MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["PD-L1 • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e osunprotafib (ABBV-CLS-484)"],"overall_status":"Recruiting","enrollment":" Enrollment 248","initiation":"Initiation: 03/09/2021","start_date":" 03/09/2021","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2025-02-14"},{"id":"a97f479a-477d-44f3-a5e0-9f9fc842a61b","acronym":"Keynote E70","url":"https://clinicaltrials.gov/study/NCT06116136","created_at":"2023-11-03T20:12:25.319Z","updated_at":"2025-02-25T14:42:27.915Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.","source_id_and_acronym":"NCT06116136 - Keynote E70","lead_sponsor":"Servier Bio-Innovation LLC","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • S95029"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 08/31/2024","start_date":" 08/31/2024","primary_txt":" Primary completion: 06/10/2026","primary_completion_date":" 06/10/2026","study_txt":" Completion: 06/01/2029","study_completion_date":" 06/01/2029","last_update_posted":"2025-02-14"},{"id":"d94f7980-52bd-4422-b97d-6ffc7470ef49","acronym":"NRG-GY031","url":"https://clinicaltrials.gov/study/NCT05950464","created_at":"2023-07-20T15:09:28.523Z","updated_at":"2025-02-25T14:42:14.385Z","phase":"Phase 1","brief_title":"Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer","source_id_and_acronym":"NCT05950464 - NRG-GY031","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PIK3CA • MSI • MYC • ARID1A • MUC16 • HEXIM1","pipe":" | ","alterations":" MSI-H/dMMR","tags":["PIK3CA • MSI • MYC • ARID1A • MUC16 • HEXIM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ZEN-3694 • tuvusertib (M1774)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 12/18/2023","start_date":" 12/18/2023","primary_txt":" Primary completion: 04/30/2026","primary_completion_date":" 04/30/2026","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2025-02-14"},{"id":"bcfa1353-7be6-4150-b82c-bf13212f8a0b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05836584","created_at":"2023-05-01T14:03:52.795Z","updated_at":"2025-02-25T15:13:28.038Z","phase":"Phase 2","brief_title":"Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer","source_id_and_acronym":"NCT05836584","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • docetaxel • capecitabine • oxaliplatin • leucovorin calcium • fluorouracil topical"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 12/06/2023","start_date":" 12/06/2023","primary_txt":" Primary completion: 10/31/2027","primary_completion_date":" 10/31/2027","study_txt":" Completion: 10/31/2027","study_completion_date":" 10/31/2027","last_update_posted":"2025-02-13"},{"id":"cb11626b-0801-40b0-ae65-d3f235f68f1d","acronym":"Iintune-1","url":"https://clinicaltrials.gov/study/NCT04420884","created_at":"2021-01-18T21:18:09.463Z","updated_at":"2025-02-25T15:18:40.036Z","phase":"Phase 1/2","brief_title":"A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT04420884 - Iintune-1","lead_sponsor":"Takeda","biomarkers":" PD-L1 • MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["PD-L1 • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • 5-fluorouracil • dazostinag (TAK-676)"],"overall_status":"Recruiting","enrollment":" Enrollment 374","initiation":"Initiation: 07/22/2020","start_date":" 07/22/2020","primary_txt":" Primary completion: 01/15/2026","primary_completion_date":" 01/15/2026","study_txt":" Completion: 01/15/2026","study_completion_date":" 01/15/2026","last_update_posted":"2025-02-12"},{"id":"00b00cab-c2ee-4273-adb9-917c1a26dc74","acronym":"PROCEADE-CRC-01","url":"https://clinicaltrials.gov/study/NCT05464030","created_at":"2022-07-19T15:55:16.853Z","updated_at":"2025-02-25T15:44:51.157Z","phase":"Phase 1","brief_title":"Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)","source_id_and_acronym":"NCT05464030 - PROCEADE-CRC-01","lead_sponsor":"EMD Serono Research \u0026 Development Institute, Inc.","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • capecitabine • leucovorin calcium • precemtabart tocentecan (M9140)"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 08/04/2022","start_date":" 08/04/2022","primary_txt":" Primary completion: 02/27/2026","primary_completion_date":" 02/27/2026","study_txt":" Completion: 02/27/2026","study_completion_date":" 02/27/2026","last_update_posted":"2025-02-11"},{"id":"743006a6-c939-4023-8010-4e3aee085ae3","acronym":"E7386-J081-102","url":"https://clinicaltrials.gov/study/NCT04008797","created_at":"2022-06-28T02:54:50.954Z","updated_at":"2025-02-25T15:18:13.404Z","phase":"Phase 1/2","brief_title":"A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor","source_id_and_acronym":"NCT04008797 - E7386-J081-102","lead_sponsor":"Eisai Inc.","biomarkers":" EGFR • KRAS • BRAF • MSI","pipe":" | ","alterations":" BRAF V600E • MSI-H/dMMR • BRAF V600 • KRAS wild-type • NRAS wild-type","tags":["EGFR • KRAS • BRAF • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • MSI-H/dMMR • BRAF V600 • KRAS wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Lenvima (lenvatinib) • doxorubicin hydrochloride • E7386"],"overall_status":"Recruiting","enrollment":" Enrollment 301","initiation":"Initiation: 07/11/2019","start_date":" 07/11/2019","primary_txt":" Primary completion: 11/30/2026","primary_completion_date":" 11/30/2026","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2025-02-11"},{"id":"2119d121-8980-4c19-8bce-e35f258e6e89","acronym":"EA2201","url":"https://clinicaltrials.gov/study/NCT04751370","created_at":"2021-02-12T13:55:42.607Z","updated_at":"2025-02-25T16:38:15.444Z","phase":"Phase 2","brief_title":"Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer","source_id_and_acronym":"NCT04751370 - EA2201","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 02/08/2022","start_date":" 02/08/2022","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-06"},{"id":"3f5aa33e-06f6-48ab-8a9d-748f65a29841","acronym":"NRG GY020","url":"https://clinicaltrials.gov/study/NCT04214067","created_at":"2021-01-18T20:31:12.388Z","updated_at":"2025-02-25T16:44:47.600Z","phase":"Phase 3","brief_title":"Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer","source_id_and_acronym":"NCT04214067 - NRG GY020","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 168","initiation":"Initiation: 04/09/2020","start_date":" 04/09/2020","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2025-02-06"},{"id":"d0aa4f16-7694-44b7-8f9e-f75259b43f62","acronym":"","url":"https://clinicaltrials.gov/study/NCT05544929","created_at":"2022-09-19T14:56:40.664Z","updated_at":"2025-02-25T16:39:18.617Z","phase":"Phase 1","brief_title":"A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers","source_id_and_acronym":"NCT05544929","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Tevimbra (tislelizumab-jsgr) • KFA115"],"overall_status":"Recruiting","enrollment":" Enrollment 180","initiation":"Initiation: 10/26/2022","start_date":" 10/26/2022","primary_txt":" Primary completion: 02/20/2026","primary_completion_date":" 02/20/2026","study_txt":" Completion: 02/20/2026","study_completion_date":" 02/20/2026","last_update_posted":"2025-02-06"},{"id":"bb8c9bbf-af0e-4c45-9940-af8cc5fdbc47","acronym":"PNACGEC","url":"https://clinicaltrials.gov/study/NCT05033392","created_at":"2021-09-02T14:53:11.733Z","updated_at":"2025-02-25T16:45:35.071Z","phase":"Phase 2","brief_title":"PD-1 Blockade With JS001 Plus Neoadjuvant Chemotherapy for Gastric/Gastroesophageal Junction Cancer","source_id_and_acronym":"NCT05033392 - PNACGEC","lead_sponsor":"Wan He","biomarkers":" PD-L1 • MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["PD-L1 • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi)"],"overall_status":"Recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 09/14/2021","start_date":" 09/14/2021","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-05"},{"id":"ed7b8404-0f3f-4d03-b259-8cbdfacd2292","acronym":"KEYNOTE-F62","url":"https://clinicaltrials.gov/study/NCT06108050","created_at":"2023-10-30T16:13:05.018Z","updated_at":"2025-02-25T16:19:13.834Z","phase":"Phase 1","brief_title":"JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors","source_id_and_acronym":"NCT06108050 - KEYNOTE-F62","lead_sponsor":"Jazz Pharmaceuticals","biomarkers":" BRAF • MSI","pipe":" | ","alterations":" MSI-H/dMMR • BRAF mutation","tags":["BRAF • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • JZP898"],"overall_status":"Recruiting","enrollment":" Enrollment 177","initiation":"Initiation: 11/07/2023","start_date":" 11/07/2023","primary_txt":" Primary completion: 11/30/2027","primary_completion_date":" 11/30/2027","study_txt":" Completion: 05/31/2028","study_completion_date":" 05/31/2028","last_update_posted":"2025-02-05"}]